Intercept Liver Disease Strategy Bets Heavily On New Surrogate Endpoints
Executive Summary
Intercept is aiming to file obeticholic acid for accelerated approval in two liver disease indications and is mining clinical outcomes data to support new surrogate endpoints with the help of a clinical network dubbed the “Supergroup.”
You may also be interested in...
Galectin Plans To Head Into NASH Pivotal Studies Without Biopsy-Evaluated Endpoint
Company is moving its galectin-3 inhibitor into Phase III in non-alcoholic steatohepatitis patients with cirrhosis – a very advanced disease setting – and also to validate endpoints that don’t require liver biopsy.
Searching For Surrogate Endpoints Requires Teamwork
Discussions between FDA and researchers during a workshop on the fatty liver conditions NAFLD/NASH clarified the status of potential surrogate endpoints for clinical trials, but indicated that much work remains to be done to ready the various options for use – and that will likely need to be a joint effort.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.